This peptide may be used to block binding activity of antibody to Parkin (# R-113-100).
Product Type:
Peptide
Format:
Lyophilized
Applications:
Block
Application Details:
Control peptide. This peptide may be used to block binding activity of antibody to Parkin (# R-113-100). Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Alternative Names:
Ubiquitin E3 ligase PRKN; Parkinson juvenile disease protein 2; Parkinson disease protein 2; PARK2; PRKN
Biosensis Brand:
Biosensis®
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
Storage:
After reconstitution keep at -20°C. Avoid repetitive freeze/thaw cycles.
Rabbit anti-Parkinson disease protein 2 (Parkin) Polyclonal Antibody (Unconjugated), suitable for WB, IHC-Frozen.
Background Info:
FUNCTION: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP and SEPT5. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene. SUBCELLULAR LOCATION: Cytoplasm. Co-localizes with STY11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. TISSUE SPECIFICITY: Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis.
Product Type:
Antibody
Antibody Type:
Polyclonal
Format:
Lyophilized
Host Animal:
Rabbit
Species Reactivity:
Human,Rat
Immunogen:
A synthetic peptide (NSLIKELHHFRILGEEQ) as part of human Parkin conjugated to KLH has been used as the immunogen.
Applications:
IHC-Frozen,WB
Antibody Isotype:
Mixed
Application Details:
IHC, WB. A dilution of 1:1000 is recommended for immunohistochemistry and 1:2000 for western blot. Nice staining is achieved in neuronal and cytoplasmic granules sections treated with citrate buffer for antigen retrieval. Few inclusions are stained but these were not positively identified as Lewy bodies. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Alternative Names:
Ubiquitin E3 ligase PRKN; Parkinson juvenile disease protein 2; Parkinson disease protein 2; PARK2; PRKN
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
Product references:
Song Y. J. C. et al (2009). Degeneration in different parkinsonian syndromes relates to astrocyte type and astrocyte protein expression. J. Neuropathol. Exp. Neurol. Oct 2009;68(10):1073-1083 Huang Y. et al (2008). LRRK2 and parkin immunoreactivity in multiple system atrophy inclusions. Acta Neuropathol. 2008 Dec;116(6):639-46.
Specificity:
This antiserum is known to be highly specific for Parkin shown by IHC and WB. This antibody is known to react with rat and human Parkin.
Storage:
After reconstitution keep aliquots at -20°C for a higher stability, and at 2-8°C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
Rabbit anti-Parkinson disease protein 2 (Parkin) Polyclonal Antibody (Unconjugated), suitable for WB, IHC-Frozen, ELISA.
Background Info:
FUNCTION: Functions within a multiprotein E3 ubiquitin ligase complex, catalyzing the covalent attachment of ubiquitin moieties onto substrate proteins. These substrates include SYT11, CCNE1, GPR37, STUB1, a 22 kDa O-linked glycosylated isoform of SNCAIP and SEPT5. May play a more general role in the ubiquitin proteasomal pathway by participating in the removal and/or detoxification of abnormally folded or damaged protein. Loss of this ubiquitin ligase activity appears to be the mechanism underlying pathogenesis of PARK2. May protect neurons against alpha synuclein toxicity, proteasomal dysfunction, GPR37 accumulation, and kainate-induced excitotoxicity. May play a role in controlling neurotransmitter trafficking at the presynaptic terminal and in calcium-dependent exocytosis. Regulates cyclin E during neuronal apoptosis. May represent a tumor suppressor gene. SUBCELLULAR LOCATION: Cytoplasm. Co-localizes with STY11 in neutrites. Co-localizes with SNCAIP in brainstem Lewy bodies. TISSUE SPECIFICITY: Highly expressed in the brain including the substantia nigra. Expressed in heart, testis and skeletal muscle. Expression is down-regulated or absent in tumor biopsies, and absent in the brain of PARK2 patients. Overexpression protects dopamine neurons from kainate-mediated apoptosis.
Product Type:
Antibody
Antibody Type:
Polyclonal
Format:
Lyophilized
Host Animal:
Rabbit
Species Reactivity:
Guinea Pig,Human,Rat
Immunogen:
A synthetic peptide (RILGEEQYNRYQQYGAEEC) as part of human Parkin conjugated to diphtheria toxoid has been used as the immunogen.
Applications:
ELISA,IHC-Frozen,WB
Antibody Isotype:
Mixed
Application Details:
IHC, WB, immunoblot, 1-site ELISA. A dilution of 1:500 to 1:2000 is recommended for these applications. This antiserum stains trigeminal motor neurons in rat brain stem. A 50 kDa band was identified in rat brain extract using western blot. Biosensis recommends optimal dilutions/concentrations should be determined by the end user.
Alternative Names:
Ubiquitin E3 ligase PRKN; Parkinson juvenile disease protein 2; Parkinson disease protein 2; PARK2; PRKN
Biosensis Brand:
Biosensis®
Conjugate:
Unconjugated
Shelf Life:
12 months after date of receipt (unopened vial).
Use:
For research use only.
Product references:
Francelin C et al (2021) BACE1 Inhibition Increases Susceptibility to Oxidative Stress by Promoting Mitochondrial Damage. Antioxidants (Basel). 10(10):1539. E. Rubio de la Torre et al (2009) Combined kinase inhibition modulates parkin inactivation. Hum Mol Genet. 2009 Mar 1;18(5):809-23. D'Agata V. et al (2009) Parkin expression profile in dopamine d3 receptor knock-out mice brains. Neurochem Res. 2009 Feb;34(2):327-32. Tamo W. et al (2007) Parkin is expressed in vascular endothelial cells. Neurosci Lett. 2007 Jun 4;419(3):199-201. Trimmer P.A. et al (2004) Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies. J Neurochem. 2004 Feb;88(4):800-12. Denison S.R. et al (2004) Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene. 2003 Nov 13;22(51):8370-8. Pawlyk A.C. et al (2003) Novel monoclonal antibodies demonstrate biochemical variation of brain parkin with age. J Biol Chem. 2003 Nov 28;278(48):48120-8. Horowitz J.M. et al (2001) Spatial distribution, cellular integration and stage development of Parkin protein in Xenopus brain. Brain Res Dev Brain Res. 2001 Jan 31;126(1):31-41.
Specificity:
This antiserum is known to specifically recognise Parkin shown by IHC and WB. This antibody is known to react with Parkin of guinea pig and rat.
Storage:
Store lyophilized antibody at 2-8°C. After reconstitution keep aliquots at -20°C for a higher stability, and at 2-8°C with an appropriate antibacterial agent. Glycerol (1:1) may be added for an additional stability. Avoid repetitive freeze/thaw cycles.
Human PARK2(E3 ubiquitin-protein ligase parkin) ELISA Kit
Product Type:
Assay & Detection
Storage Temp:
4°C
Applications:
ELISA
Biosite Brand:
BioSite ELISA
Species Reactivity:
human
UniProt No:
O60260
Cookies:
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.